FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: Single-center experience

Annals of Hematology

Volumn 82, Issue 4, 2003, Pages 231-235

  Pastore, D ^a   Specchia, G ^a,b   Carluccio, P ^a   Liso, A ^a   Mestice, A ^a   Rizzi, R ^a   Greco, G ^a   Buquicchio, C ^a   Liso, V ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Acute myeloid leukemia; FLAG IDA; Refractory; Relapsed

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRAIN HEMORRHAGE; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANDIDA TROPICALIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; EXPERIENCE; FEMALE; FOLLOW UP; FUNGEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; NEUTROPHIL; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; REFRACTORY PERIOD; SALVAGE THERAPY; THROMBOCYTE; WORLD HEALTH ORGANIZATION;

EID: 0038180704     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0624-2     Document Type: Article

References (31)

1. Angelov L, Brandwein J, Baker M (1991) Results of therapy for acute myeloid leukemia in first relapse. Leuk Lymphoma 6:15-24
2. Bassan R, Lerede T, Buelli M, Boleri G, Bellavita P, Rambaldi A, Barbui T (1998) A new combination of carboplatin, highdose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia. Hematologica 83:422-427
3. Bennet JM, Catowsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:620-625
4. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J (1991) Results of randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myeloid leukemia. Blood 77:1666-1671
5. Carella AM, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, Montillo M, Iacopino P, Mirto S, Pagano L (1993) Idarubicin in combination with intermediate dose of cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group. Leukemia 7:196
6. Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gatti A, Cerri R, Celesti L, Vallebella E, Sessarego M, Patrone F, Ghio R, Damasco E, Gobbi M (1996) High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 81:513-520
7. Davis C, Rohatiner A, Amess J, Lim J, Lister TA (1993) The management of recurrent acute myelogenous leukemia at a single center over a fifteen year period. Br J Haematol 83:404-411
8. De la Rubia J, Regadera A, Martin G, Cervera J, Sanz G, Martinez J, Garcia I, Andreu R, Moscardo F, Jimenez C, Molla S, Benlloch L, Sanz M (2002) FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. Leuk Res 26:725-730
9. Estey E, Plunkett W, Gandhi V, Rios M, Kantarjian H, Keating MJ (1993) Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 9:343-350
10. Ferra' C, Berlanga J, Gallardo D, Ancin I, Marin D, Gonzales J, Peris J, Munoz J, Sarra J, Granena A (2000) Mitoxantrone, etoposide, carboplatinum and ARA-C combination therapy (MECA) in refractory and relapsed acute leukemia. Leuk Lymphoma 39:583-590
11. Ferrara F, Melillo L, Montillo M, Leoni F, Pinto A, Mele G, Mirto S (1999) Fludarabine, cytarabine, and G-CSF(FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation. Ann Hematol 78:380-384
12. Gandhi V, Estey E, Keating M, Plunkett W (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116-124
13. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A (1998) The importance of diagnostic cytogenetic on outcome in AML: analysis of 1612 patients entered into the MRC AML 14 trial. The Medical Research Council Adult and Children's Leukemia Working Parties. Blood 92:2322-2333
14. Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hunstein W (1988) Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia: an active and well tolerated regimen. J Clin Oncol 6:213
15. Huhmann IM, Watzke HH, Geisller K, Gisslinger H, Jager U, Knobl P, Pabinger I, Korninger L, Mannhalter C, Mitterbauer G, Schwarzinger I, Kahls P, Haas OA, Lechner K (1996) FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol 73:265-271
16. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ (1989) Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7:1071-1080
17. Kern W, Aul C, Maschmeyer G, Schonrock-Nabulsi R, Ludwig WD, Bartholomaus A, Bettelheim P, Wormann B, Buchner T, Hiddemann W (1998) Superiority of high dose over intermediate dose cytarabine arabinoside in the treatment of patients with high-risk acute myeloid leukemia. Leukemia 12:1049-1055
18. Kern W, Schleyer E, Braess J, Wittmer E, Ohnesorge J, Unterhalt M, Wormann B, Buchner T, Hiddemann W (2001) Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias. Ann Hematol 80:334-339
19. Liso V, Albano F, Pastore D, Carluccio P, Mele G, Lamacchia M, Mestice A, Specchia G (2000) Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult myeloid leukemia. Haematologica 85:1285-1290
20. Liso V, Iacopino P, Avvisati G, Petti MC, Broccia G, Carotenuto M, Falda M, Fazzi P, Lazzarino M, Leoni P, Mirto S, Pucci G, Nobile F, Nosari AM, Specchia G, Stasi R, Tabilio A, Mandelli F (1996) Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Leukemia 110:1443-1452
21. Michelutti A, Michieli M, Damiani D, Melli C, Ermacora A, Grimaz S, Candoni A, Russo D, Fanin R, Baccarani M, et al. (1997) Effect of fludarabine and arabinosylcytosine on multidrug-resistant cells. Haematologica 82:143-147
22. Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, Zagonel V, Mele G, Tedeschi A, Ferrara F (1998) Fludarabine, cytarabine and G-CSF for the treatment of poor risk acute myeloid leukemia. Am J Hematol 58:105-109
23. Nokes TJ, Johnson S, Harvey D, Goldstone AH (1997) FLAG is a useful regimen for poor prognosis adult myeloid leukemia and myelodysplastic syndromes. Leuk Lymphoma 27:93-101
24. Ossenkoppele G, Graveland W, Sonneveld P, Daenen S, Biesma D, Verdonk L, Schaafsma M, Westveer P, Peters G, Noordhuis P, Maas P, Sellesla D, van der Holt B, Delforge M, Lowenberg B, Verhoef G (2002) Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and GCSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML (abstract 3130). Blood 100:792a
25. Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM, Samaratunga IR, Grace R, Gover PA, Mufti GJ (1997) Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for treatment of poor-risk myelodysplastic syndromes and acute leukemia. Br J Haematol 99:939-944
26. Thalhammer F, Geissler K, Jager U, Kyrle PA, Pabinger I, Mitterbauer M, Gisslinger H, Knobl P, Laczika K, Schneider B, Ilaas OA, Lechmer K (1996) Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol 72:216-222
27. Vignetti M, Orsini E, Petti MC, Moleti MR, Andrizzi C, Pinto RM, Amdori S, Meloni G (1996) Probability of long term disease free survival for acute myeloid leukemia patients after first relapse: a single center experience. Ann Oncol 7:933-938
28. Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Testoni N, Clavio M, Cenacchi A, Gamberi B, Carrara B, Gobbi M, Tura S(1994) FLAG (fludarabine+high dose cytarabine +GCSF): an effective and tolerable protocol for the treatment of "poor risk" acute myeloid leukemia. Leukemia 8:1842-1846
29. Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kimgsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M (1996) A randomized investigation of high dose versus standard dose cytosine arabinoside with daunorubicin in patients with untreated acute myeloid leukemia: a southwest oncology group study. Blood 88:2841-2851
30. Wiernick PH, Banks PL, Case DC, Arlin ZA, Periman PO, Todd MB, Ritch PS, Ence RE, Weitberg AB (1992) Cytarabine plus idarubucin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79:313-320
31. World Health Organization (1979) A handbook for reporting results of cancer treatment. WHO publication, Geneva